Vicky Gregg - Quest Diagnostics Independent Director
| DGX Stock | USD 163.32 0.00 0.00% |
Director
Ms. Vicky B. Gregg is Independent Director of the Company. Ms. Gregg retired as Chief Executive Officer of Blue Cross Blue Shield of Tennessee in 2012. Prior to becoming CEO in 2003, Ms. Gregg served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg served as a member of the U.S. National Institutes of Health Commission on Systemic Interoperability. She currently serves on the boards of Acadia Healthcare Company, Inc. and the Electric Power Board of Chattanooga. Previously, Ms. Gregg served on several national boards, including TeamHealth Holdings, Inc. from 2013 to 2017, First Horizon National Corporation from 2011 to 2015, Chair of Americas Health Insurance Plans from 2010 to 2011, the BlueCross BlueShield Association, Chair of the National Institute for Healthcare Management in 2012, and the Healthcare Leadership Council. Ms. Gregg has extensive executive and advisory experience, including in general management and strategic planning, with a range of health care organizations, and extensive experience with healthcare issues and the operation of the U.S. healthcare system, including as a practicing nurse. since 2014.
| Age | 65 |
| Tenure | 10 years |
| Address | 500 Plaza Drive, Secaucus, NJ, United States, 07094 |
| Phone | 973 520 2700 |
| Web | https://www.questdiagnostics.com |
Vicky Gregg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Vicky Gregg against Quest Diagnostics stock is an integral part of due diligence when investing in Quest Diagnostics. Vicky Gregg insider activity provides valuable insight into whether Quest Diagnostics is net buyers or sellers over its current business cycle. Note, Quest Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quest Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Vicky Gregg over six months ago Disposition of 2500 shares by Vicky Gregg of Acadia Healthcare at 85.56 subject to Rule 16b-3 |
Quest Diagnostics Management Efficiency
The company has Return on Asset of 0.0566 % which means that on every $100 spent on assets, it made $0.0566 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1322 %, implying that it generated $0.1322 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.14 in 2024. Return On Capital Employed is likely to drop to 0.10 in 2024. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.99 in 2024, whereas Total Assets are likely to drop slightly above 8.5 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Reese | Charles River Laboratories | 75 | |
| George Scangos | Agilent Technologies | 72 | |
| Elisha Finney | Mettler Toledo International | 59 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| Thomas Salice | Waters | 61 | |
| Colleen Goggins | IQVIA Holdings | 66 | |
| Sue Rataj | Agilent Technologies | 63 | |
| Linda Baddour | Waters | 62 | |
| Ronald Rittenmeyer | IQVIA Holdings | 73 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Martin Mackay | Charles River Laboratories | 65 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Michael Kelly | Mettler Toledo International | 64 | |
| Richard Wallman | Charles River Laboratories | 69 | |
| John Connaughton | IQVIA Holdings | 54 | |
| George Massaro | Charles River Laboratories | 73 | |
| Robert Bertolini | Charles River Laboratories | 59 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Hans Bishop | Agilent Technologies | 56 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0566 |
Quest Diagnostics Leadership Team
Elected by the shareholders, the Quest Diagnostics' board of directors comprises two types of representatives: Quest Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest Diagnostics' management team and ensure that shareholders' interests are well served. Quest Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Plewman, Senior Services | ||
| Gail Wilensky, Independent Director | ||
| Kristin Esq, Senior Officer | ||
| Stephen Rusckowski, CEO and President Director and Member of Executive Committee | ||
| Murali Balakumar, Chief VP | ||
| Wright Lassiter, Independent Director | ||
| Gary Pfeiffer, Independent Director | ||
| Vicky Gregg, Independent Director | ||
| Cecilia McKenney, Senior Officer | ||
| Helen Torley, Independent Director | ||
| Michael Prevoznik, Senior Vice President General Counsel | ||
| Tracey Doi, Independent Director | ||
| Karthik Kuppusamy, Senior Solutions | ||
| Catherine Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing | ||
| Manuel Mendez, Senior Vice President Chief Commercial Officer | ||
| Gabrielle Wolfson, Senior Vice President and Chief Information and Digital Officer | ||
| Carrie Manner, Senior Vice President - Advanced Diagnostics | ||
| Sam Samad, Executive CFO | ||
| Dermot Shorten, MA Strategy | ||
| Shawn Bevec, Executive Director Investor Relations | ||
| Timothy Main, Independent Director | ||
| Michael Deppe, Vice President Corporate Controller and Chief Accounting Officer and Principal Accounting Officer | ||
| Mark Guinan, Chief Financial Officer, Executive Vice President | ||
| Daniel Stanzione, Non-Executive Chairman of the Board | ||
| Gary Samuels, Senior Officer | ||
| Michael JD, Senior Counsel | ||
| Denise Morrison, Independent Director | ||
| James Davis, Executive Vice President, General Diagnostics | ||
| Timothy Ring, Lead Independent Director |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quest Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 24.34 B | ||||
| Shares Outstanding | 111.61 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 91.59 % | ||||
| Number Of Shares Shorted | 2.38 M | ||||
| Price To Earning | 14.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.